Akèy › Leksemi mieloïd egi › New York › New York City
Etid klinik pou Leksemi mieloïd egi nan New York City, NY
51 etid pou Leksemi mieloïd egi ap chèche patisipan nan sit nan ak bò kote New York City (nan yon distans apeprè 30 mil). Louvri yon etid pou wè ki moun ki ka patisipe ak kijan pou kontakte ekip etid la.
Tèks ofisyèl etid la (Anglè)
Ap chèche patisipan pou yon etid? Mete l anwo paj sa a — $99 pou 30 jou →
MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)
Ap rekriteFaz 2
- Mount Sinai Hospital, New York
- Memorial Sloan Kettering Cancer Center, New York
A Study to Find the Highest Dose of Cedazuridine and Decitabine Combination With Filgrastim as a Treatment Option After Hematopoietic Stem Cell Transplant in Children With High-Risk Acute Myeloid Leukemia
Ap rekriteFaz 1
- Memorial Sloan Kettering Cancer Center, New York
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
Ap rekriteEtid obsèvasyonVolontè an sante akeyi
- NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center, New York
Testing the Anti-cancer Drug, Cirtuvivint, and Its Combination With ASTX727 to Improve Outcomes in Patients With Acute Myeloid Leukemia and Myelodysplastic Syndromes
Ap rekriteFaz 1
- Memorial Sloan Kettering Cancer Center, New York
A Phase 1 Study of Orca-Q in Recipients Undergoing Allogeneic Transplantation for Hematologic Malignancies
Ap rekriteFaz 1
- Memorial Sloan Kettering Cancer Center, New York
Comparing Cytarabine + Daunorubicin Therapy Versus Cytarabine + Daunorubicin + Venetoclax Versus Venetoclax + Azacitidine in Younger Patients With Intermediate Risk AML (A MyeloMATCH Treatment Trial)
Ap rekriteFaz 2
- Mount Sinai Hospital, New York
- Memorial Sloan Kettering Cancer Center, New York
A Study of Bleximenib, Venetoclax and Azacitidine For Treatment of Participants With Newly Diagnosed Acute Myeloid Leukemia (AML)
Ap rekriteFaz 3
- Memorial Sloan Kettering Cancer Center, New York
- New York Presbyterian - Weill Cornell, New York
Comparing New Treatments for People With Newly Diagnosed Acute Myeloid Leukemia That Has an IDH2 Gene Change (A MyeloMATCH Treatment Trial)
Ap rekriteFaz 2
- Memorial Sloan Kettering Cancer Center, New York
Testing New Therapies for Patients With Acute Myeloid Leukemia Who Are Newly Diagnosed and Have Not Yet Started Treatment (A MyeloMATCH Treatment Trial)
Ap rekriteFaz 2
- Mount Sinai Hospital, New York
- Memorial Sloan Kettering Cancer Center, New York
A Study of CRD3874-SI in People With Leukemia
Ap rekriteFaz 1
- Memorial Sloan Kettering Cancer Center (All Protocol Activities), New York
Venetoclax and HMA Treatment of Older and Unfit Adults With FLT3 Mutated Acute Myeloid Leukemia (AML) (A MyeloMATCH Treatment Trial)
Ap rekriteFaz 2
- Memorial Sloan Kettering Cancer Center, New York
A Multi-Site Break Through Cancer Trial: Phase II Study Investigating Dual Inhibition of BCL2 and Menin in AML MRD Using the Combination of Venetoclax and Revumenib
Ap rekriteFaz 1/2
- Memorial Sloan Kettering Cancer Center, New York
A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations
Ap rekriteFaz 3
- Laura and Isaac Perlmutter Cancer Center at NYU Langone, New York
- NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center, New York
- Memorial Sloan Kettering Cancer Center, New York
- ak 1 plis
A Study of Revumenib in R/R Leukemias Including Those With an MLL/KMT2A Gene Rearrangement or NPM1 Mutation
Ap rekriteFaz 1/2
- Montefiore Medical Center, New York
Evaluation of Two Dose Levels of Quizartinib as Maintenance in FLT3-ITD (+) Acute Myeloid Leukemia Patients in Complete Remission
Ap rekriteFaz 2
- Weill Cornell, New York
Cord Blood Transplant in Adults With Blood Cancers
Ap rekriteFaz 2
- Memorial Sloan Kettering Cancer Center, New York
Eganelisib as Monotherapy and in Combination With Cytarabine in Relapsed/Refractory AML
Ap rekriteFaz 1
- Memorial Sloan Kettering Cancer Center, New York
- Memorial Sloan Kettering Cancer Center, New York
- Montefiore Medical Center, New York
The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study
Ap rekriteFaz 1/2
- NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center, New York
- Memorial Sloan Kettering Cancer Center, New York
Venetoclax in Children With Relapsed Acute Myeloid Leukemia (AML)
Ap rekriteFaz 3
- Columbia University Irving Medical Center, New York
- Memorial Sloan Kettering Cancer Center - New York, New York
Studies to Assess Ziftomenib in Combination With Ven+Aza or 7+3 in Patients With Untreated NPM1-m or KMT2A-r AML
Ap rekriteFaz 3
- Icahn School of Medicine at Mount Sinai, New York
- Columbia University, New York
- Weill Cornell Medical Center, New York
Safety and Tolerability of Ziftomenib Combinations in Patients With Relapsed/Refractory Acute Myeloid Leukemia
Ap rekriteFaz 1
- Memorial Sloan Kettering Cancer Center, New York
- Weill Cornell Medical College-NY Presbyterian Hospital, New York
ICP-248 in Combination With Azacitidine for the Treatment in Patients With Myeloid Malignancies
Ap rekriteFaz 1
- NYU Langone Health, New York
Olutasidenib DDI Study in Patients With IDH1 Mutation Positive Malignancies
Ap rekriteFaz 4
- New York Presbyterian Hospital-Columbia University Medical Center, New York
Study of Revumenib, Azacitidine, and Venetoclax in Pediatric and Young Adult Patients With Refractory or Relapsed Acute Myeloid Leukemia
Ap rekriteFaz 1
- Memorial Sloan- Kettering Cancer Center, New York
Study of AZD3632 Monotherapy or in Combination With Anticancer Agents in Participants With Advanced Haematologic Malignancies With KMT2Ar, NPM1m, or Other Genotypes Associated With HOX Overexpression
Ap rekriteFaz 1/2
- Research Site, New York
A Study of the Combination of Ivosidenib, Azacitidine, and Venetoclax Followed by Ivosidenib Alone in People With Acute Myeloid Leukemia
Ap rekriteFaz 2
- Memorial Sloan Kettering Cancer Center (All Protocol Activities), New York
Trial of Orca-T Following Reduced Intensity or Nonmyeloablative Conditioning in Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome
Ap rekriteFaz 2
- Weill Cornell Medicine - New York Presbyterian Hospital, New York
A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)
Ap rekriteEtid obsèvasyon
- New York University Langone Medical Center, New York
- New York Presbyterian Hospital at Cornell, New York
- Mount Sinai Medical Center - New York, New York
- ak 3 plis
A Study of Revumenib and Mezigdomide in People With Leukemia
Ap rekriteFaz 1/2
- Memorial Sloan Kettering Cancer Center (All Protocol Activities), New York
A Study of CD371-YSNVZIL-18 CAR T Cells in People With Acute Myeloid Leukemia
Ap rekriteFaz 1
- Memorial Sloan Kettering Cancer Center (All protocol activites), New York
A Study of Gilteritinib in Combination With Ivosidenib or Enasidenib in People With Acute Myeloid Leukemia (AML)
Ap rekriteFaz 1
- Memorial Sloan Kettering Cancer Center (All Protocol Activities), New York
A Study of Natural Killer Cells in Combination With Atezolizumab in People With Acute Myelogenous Leukemia
Ap rekriteFaz 1
- Memorial Sloan Kettering Cancer Center, New York
BAL0891 in Patients With Advanced Solid Tumors or Relapsed or Refractory Acute Myeloid Leukemia
Ap rekriteFaz 1
- New York Medicine-New York-Presbyterian Hospital, New York
- Montefiore Medical Center - Montefiore Hospital, New York
Cord Blood Transplantation in Children and Young Adults With Blood Cancer
Ap rekriteFaz 2
- Memorial Sloan Kettering Cancer Center (All Protocol Activities), New York
A Multi-phase Study of ASTX030 (Azacitidine and Cedazuridine) in Myeloid Neoplasm Alone or in Combination With Venetoclax in AML (AZTOUND Study)
Ap rekriteFaz 2/3
- Perlmutter Cancer Center - 34th Street, New York
- Icahn School of Medicine at Mount Sinai, New York
Imetelstat Combinations in Relapsed AML
Ap rekriteFaz 1
- Icahn School of Medicine at Mount Sinai, New York
A Study of GLB-001 in Patients With Relapsed or Refractory Acute Myeloid Leukemia or Relapsed or Refractory Higher Risk Myelodysplastic Syndromes
Ap rekriteFaz 1
- Icahn School of Medicine at Mount Sinai, New York
Safety and Proof-of-Concept Study of RPT1G in Adults With Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndromes
Ap rekriteFaz 1
- Memorial Sloan Kettering Cancer Center, New York
A Platform Protocol to Investigate Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis in Patients With Hematologic Malignancies Undergoing Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation
Ap rekriteFaz 2
- Memorial Sloan Kettering, New York
A Study of CBX-250 in Participants With Relapsed or Refractory Myeloid Leukemias
Ap rekriteFaz 1
- Memorial Sloan Kettering Cancer Center, New York
A Study to Investigate the Safety and Tolerability of Ziftomenib in Combination With Venetoclax/Azacitidine, Venetoclax, 7+3, or 7+3+Quizartinib in Patients With AML
Ap rekriteFaz 1
- New York - Presbyterian / Weill Cornell Medicine, New York
- Mount Sinai - Ruttenberg Treatment Center, New York
- Columbia University Medical Center, New York
Cord Blood Transplant in Children and Young Adults With Blood Cancers and Non-malignant Disorders
Ap rekriteFaz 2
- Memorial Sloan Kettering Cancer Center, New York
A Study of ADCLEC.syn1 in People With Acute Myeloid Leukemia
Ap rekriteFaz 1
- Memorial Sloan Kettering Cancer Center, New York
A Study of Azacitidine and Venetoclax in People With Acute Myeloid Leukemia (AML)
Ap rekriteFaz 2
- Memorial Sloan Kettering Cancer Center (All Protocol Activities), New York
CLN-049 in Patients With Relapsed/Refractory Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)
Ap rekriteFaz 1
- New York University, New York
Pharmacokinetic and Safety Study of MRX-2843 in Adolescents and Adults With Relapsed/Refractory AML, ALL, or MPAL
Ap rekriteFaz 1
- Memorial Sloan Kettering Cancer Center, New York
A Study of BH-30236 in Relapsed/ Refractory Acute Myelogenous Leukemia and Higher Risk Myelodysplastic Syndrome
Ap rekriteFaz 1
- Memorial Sloan Kettering Cancer Center, New York
Study of REM-422 in Patients With AML or Higher Risk MDS
Ap rekriteFaz 1
- Memorial Sloan Kettering, New York
A Clinical Trial of BP1002 in Patients With Refractory/Relapsed Acute Myeloid Leukemia (AML)
Ap rekriteFaz 1
- Weill Cornell Medical College - NewYork-Presbyterian Hospital, New York
Clinical Trial of BP1001 in Combination With With Venetoclax Plus Decitabine in AML
Ap rekriteFaz 2
- Laura & Isaac Pe lmutter Cancer Center at NYU Langone Health, New York
- Weill Cornell Medical College - New York - Presbyterian Hospital, New York
A Study of BTX-A51 in People With Relapsed or Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome
Ap rekriteFaz 1
- Memorial Sloan-Kettering Cancer Center, New York
Etid Leksemi mieloïd egi nan lòt vil
- Houston, TX85 etid
- Boston, MA44 etid
- Seattle, WA41 etid
- Baldwin Park, CA40 etid
- Columbus, OH35 etid
- Philadelphia, PA34 etid
- Durham, NC33 etid
- Atlanta, GA31 etid
- Tampa, FL29 etid
- Chicago, IL26 etid
- Portland, OR25 etid
- Washington, DC24 etid
Lòt etid nan New York City
- Kansè nan tete136 etid
- Kansè Poumon ki pa ti selil121 etid
- Kansè (tout kalite)109 etid
- Kansè pwostat103 etid
- Kansè Metastatik93 etid
- Kansè kolorektal78 etid
- Kansè ovè69 etid
- Kansè poumon60 etid
- Myelom Miltip60 etid
- Kansè pankreyas60 etid
- Kansè Endomèt52 etid
- Ensifizyans kadyak51 etid
Sous ClinicalTrials.gov, done yo ranmase Oct 6, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.